Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort ascending Project Status Date Submission Received Date Recommendation Issued
Lucentis Ranibizumab Myopic choroidal neovascularisation List with criteria/condition Complete
Actemra Tocilizumab Arthritis, rheumatoid List with criteria/condition Complete
Revolade Eltrombopag Thrombocytopenia associated with chronic hepatitis c infection List with criteria/condition Complete
Kalydeco Ivacaftor Cystic Fibrosis, CFTR gating mutations List with criteria/condition Complete
Xeljanz Tofacitinib Arthritis, rheumatoid List with criteria/condition Complete
Prezcobix Darunavir/cobicistat HIV Infection List with criteria/condition Complete
Apidra Insulin glulisine Diabetes, Mellitus (Type 1 & 2) List in a similar manner to other drugs in class Complete
Olmetec Plus Olmesartan medoxomil + hydrochlorothiazide Hypertension List in a similar manner to other drugs in class Complete
Olmetec Olmesartan medoxomil Hypertension List in a similar manner to other drugs in class Complete
Fosavance 70/5600 Alendronate sodium / cholecalciferol Osteoporosis List in a similar manner to other drugs in class Complete